Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Lineage Cell Therapeutics (LCTX) Accumulated Depreciation & Amortization: 2011-2025

Historic Accumulated Depreciation & Amortization for Lineage Cell Therapeutics (LCTX) over the last 13 years, with Sep 2025 value amounting to $2.6 million.

  • Lineage Cell Therapeutics' Accumulated Depreciation & Amortization rose 48.70% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 42.21%. This contributed to the annual value of $1.9 million for FY2024, which is 37.33% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization stood at $2.6 million, which was up 8.94% from $2.4 million recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $150.0 million for Q1 2022, and its period low was -$440.4 million during Q4 2022.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $2.0 million (2025), whereas its average is $39.5 million.
  • Examining YoY changes over the last 5 years, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization showed a top increase of 88,384.85% in 2022 and a maximum decrease of 277,092.45% in 2022.
  • Over the past 5 years, Lineage Cell Therapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $159,000 in 2021, then crashed by 277,092.45% to -$440.4 million in 2022, then spiked by 100.31% to $1.4 million in 2023, then soared by 37.33% to $1.9 million in 2024, then surged by 48.70% to $2.6 million in 2025.
  • Its last three reported values are $2.6 million in Q3 2025, $2.4 million for Q2 2025, and $2.0 million during Q1 2025.